Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Shares Sold by Allspring Global Investments Holdings LLC

Allspring Global Investments Holdings LLC decreased its holdings in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Free Report) by 6.8% in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 168,721 shares of the company's stock after selling 12,401 shares during the period. Allspring Global Investments Holdings LLC owned approximately 0.44% of Tarsus Pharmaceuticals worth $8,667,000 at the end of the most recent quarter.

Other hedge funds also recently bought and sold shares of the company. Crowley Wealth Management Inc. acquired a new position in Tarsus Pharmaceuticals during the fourth quarter worth $25,000. GF Fund Management CO. LTD. acquired a new position in Tarsus Pharmaceuticals during the fourth quarter worth $44,000. Quarry LP acquired a new position in shares of Tarsus Pharmaceuticals during the 4th quarter valued at about $166,000. HighTower Advisors LLC acquired a new position in shares of Tarsus Pharmaceuticals during the 4th quarter valued at about $207,000. Finally, Summit Investment Advisors Inc. boosted its position in shares of Tarsus Pharmaceuticals by 6.8% during the 4th quarter. Summit Investment Advisors Inc. now owns 3,848 shares of the company's stock valued at $213,000 after acquiring an additional 244 shares during the last quarter. Institutional investors and hedge funds own 90.01% of the company's stock.

Tarsus Pharmaceuticals Trading Up 1.6%

Shares of Tarsus Pharmaceuticals stock traded up $0.63 during trading hours on Friday, hitting $41.08. The company's stock had a trading volume of 274,097 shares, compared to its average volume of 686,318. The firm has a fifty day moving average of $43.34 and a 200-day moving average of $47.51. The company has a debt-to-equity ratio of 0.21, a quick ratio of 5.54 and a current ratio of 5.57. Tarsus Pharmaceuticals, Inc. has a twelve month low of $20.08 and a twelve month high of $57.28. The stock has a market cap of $1.73 billion, a price-to-earnings ratio of -15.05 and a beta of 0.80.

Tarsus Pharmaceuticals (NASDAQ:TARS - Get Free Report) last issued its quarterly earnings data on Thursday, May 1st. The company reported ($0.64) EPS for the quarter, topping the consensus estimate of ($0.69) by $0.05. Tarsus Pharmaceuticals had a negative net margin of 44.91% and a negative return on equity of 39.72%. The firm had revenue of $78.34 million for the quarter, compared to analyst estimates of $72.50 million. Research analysts forecast that Tarsus Pharmaceuticals, Inc. will post -3.17 EPS for the current year.

Analyst Upgrades and Downgrades

TARS has been the topic of several recent research reports. HC Wainwright raised shares of Tarsus Pharmaceuticals to a "buy" rating and set a $72.00 price target on the stock in a research report on Tuesday, May 27th. Oppenheimer assumed coverage on shares of Tarsus Pharmaceuticals in a report on Monday, June 2nd. They issued an "outperform" rating and a $75.00 target price on the stock. Wall Street Zen lowered shares of Tarsus Pharmaceuticals from a "buy" rating to a "hold" rating in a report on Thursday, May 22nd. Guggenheim boosted their target price on shares of Tarsus Pharmaceuticals from $78.00 to $84.00 and gave the company a "buy" rating in a report on Friday, May 2nd. Finally, The Goldman Sachs Group raised their target price on Tarsus Pharmaceuticals from $46.00 to $51.00 and gave the stock a "neutral" rating in a research note on Monday, May 5th. Two investment analysts have rated the stock with a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, Tarsus Pharmaceuticals presently has a consensus rating of "Moderate Buy" and an average price target of $66.67.

About Tarsus Pharmaceuticals

Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.